CASI Pharmaceuticals (CASI) Expected to Announce Quarterly Earnings on Wednesday

CASI Pharmaceuticals (NASDAQ:CASI) is anticipated to announce its resultson Wednesday, April 29th. Analysts expect the company to announce earnings of ($0.36) per share for the quarter.

CASI Pharmaceuticals Price Performance

Shares of NASDAQ CASI opened at $0.21 on Wednesday. The company has a market cap of $2.55 million, a P/E ratio of -0.07 and a beta of 0.91. CASI Pharmaceuticals has a 52 week low of $0.21 and a 52 week high of $3.09. The business has a 50-day simple moving average of $0.33 and a two-hundred day simple moving average of $0.87.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of CASI Pharmaceuticals in a report on Monday, December 29th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $4.00.

Hedge Funds Weigh In On CASI Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CASI. Two Sigma Investments LP purchased a new stake in shares of CASI Pharmaceuticals in the 3rd quarter valued at about $55,000. Woodline Partners LP grew its holdings in shares of CASI Pharmaceuticals by 64.9% during the first quarter. Woodline Partners LP now owns 164,365 shares of the biotechnology company’s stock worth $355,000 after purchasing an additional 64,675 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of CASI Pharmaceuticals by 2,013.3% during the third quarter. Bank of America Corp DE now owns 254,884 shares of the biotechnology company’s stock worth $423,000 after purchasing an additional 242,823 shares in the last quarter. 22.23% of the stock is currently owned by hedge funds and other institutional investors.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of innovative therapies in oncology and immunology. The company leverages a combination of small‐molecule targeted drugs and biologics to address high‐unmet medical needs in cancer and autoimmune diseases. CASI’s R&D efforts emphasize the discovery and advancement of compounds that modulate key signaling pathways, with a goal of delivering differentiated treatment options to patients worldwide.

The company’s lead clinical candidate is famitinib, a multi‐targeted tyrosine kinase inhibitor that has been evaluated in various solid tumors, including gastric, breast and renal cancers.